July 2025
1. KORN SM, Qian Z, Zurl H, Hansen N, et al
   Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.
   Cancer Imaging. 2025;25:86.
   

   >> Share

   
   
2. YANG L, Jin P, Wang X, Li Z, et al
   Development and validation of a novel clinical-radiological-pathological scoring system for preoperative prediction of extraprostatic extension in prostate cancer: a multicenter retrospective study.
   Cancer Imaging. 2025;25:83.
   

   >> Share

   
   June 2025
3. BIAN L, Liu F, Peng Y, Liu X, et al
   Using radiomics model for predicting extraprostatic extension with PSMA PET/CT studies: a comparative study with the Mehralivand grading system.
   Cancer Imaging. 2025;25:77.
   

   >> Share

   
   April 2025
4. MOAVENZADEH SR, Chan DY, Adams ES, Deivasigamani S, et al
   Evaluation of 3D ARFI imaging of prostate cancer: diagnostic reliability and concordance with MpMRI.
   Cancer Imaging. 2025;25:55.
   

   >> Share

   
   
5. ZEDAN AH, Gade JS, Zieger KEA, Poulsen MH, et al
   Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014-2024.
   Cancer Imaging. 2025;25:54.
   

   >> Share

   
   March 2025
6. SUN Z, Wu P, Zhao T, Gao G, et al
   Deep learning-based fully automated detection and segmentation of pelvic lymph nodes on diffusion-weighted images for prostate cancer: a multicenter study.
   Cancer Imaging. 2025;25:37.
   

   >> Share

   
   
7. POROES F, Karampa P, Sartoretti T, Najberg H, et al
   Additional findings in prostate MRI.
   Cancer Imaging. 2025;25:29.
   

   >> Share

   
   January 2025
8. HUANG X, Ye H, Hu Y, Lei Y, et al
   Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.
   Cancer Imaging. 2025;25:1.
   

   >> Share

   
   October 2024
9. BURGARD C, Rosar F, Larsen E, Khreish F, et al
   Outstanding increase in tumor-to-background ratio over time allows tumor localization by [(89)Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
   Cancer Imaging. 2024;24:132.
   

   >> Share

   
   September 2024
10. VENTURA D, Rassek P, Schindler P, Akkurt BH, et al
    Early treatment response assessment with [(177)Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.
    Cancer Imaging. 2024;24:126.
    

    >> Share

    
    August 2024
11. HARSINI S, Martineau P, Plaha S, Saprunoff H, et al
    Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Cancer Imaging. 2024;24:117.
    

    >> Share

    
    
12. XU L, Peng Q, Zhang G, Zhang D, et al
    Development of preoperative nomograms to predict the risk of overall and multifocal positive surgical margin after radical prostatectomy.
    Cancer Imaging. 2024;24:104.
    

    >> Share

    
    July 2024
13. FURMAN B, Falick Michaeli T, Den R, Ben Haim S, et al
    Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.
    Cancer Imaging. 2024;24:96.
    

    >> Share

    
    
14. KALLIS K, Conlin CC, Zhong AY, Hussain TS, et al
    Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer.
    Cancer Imaging. 2024;24:89.
    

    >> Share

    
    
15. YANG J, Xiao L, Zhou M, Li Y, et al
    [(68)Ga]Ga?PSMA?617 PET-based radiomics model to identify candidates for active surveillance amongst patients with GGG 1-2 prostate cancer at biopsy.
    Cancer Imaging. 2024;24:86.
    

    >> Share

    
    
16. GROSS M, Eisenhuber E, Assinger P, Schima R, et al
    MRI-guided in-bore biopsy of the prostate - defining the optimal number of cores needed.
    Cancer Imaging. 2024;24:81.
    

    >> Share

    
    May 2024
17. AYATI N, McIntosh L, Buteau J, Alipour R, et al
    Comparison of quantitative whole body PET parameters on [(68)Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prosta
    Cancer Imaging. 2024;24:57.
    

    >> Share

    
    April 2024
18. KOLADE OU, Brink A, Ayeni AO, More S, et al
    Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
    Cancer Imaging. 2024;24:46.
    

    >> Share

    
    February 2024
19. YAZDANI E, Karamzadeh-Ziarati N, Cheshmi SS, Sadeghi M, et al
    Automated segmentation of lesions and organs at risk on [(68)Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR.
    Cancer Imaging. 2024;24:30.
    

    >> Share

    
    
20. ROSAR F, Burgard C, Larsen E, Khreish F, et al
    [(89)Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [(68)Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
    Cancer Imaging. 2024;24:27.
    

    >> Share

    
    
21. GUERRA A, Orton MR, Wang H, Konidari M, et al
    Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
    Cancer Imaging. 2024;24:24.
    

    >> Share

    
    
22. HU C, Qiao X, Hu C, Cao C, et al
    The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
    Cancer Imaging. 2024;24:23.
    

    >> Share

    
    January 2024
23. MA Y, Gao F
    Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.
    Cancer Imaging. 2024;24:19.
    

    >> Share

    
    December 2023
24. DONNERS R, Figueiredo I, Westaby D, Koh DM, et al
    Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
    Cancer Imaging. 2023;23:121.
    

    >> Share

    
    November 2023
25. PENG Q, Xu L, Zhang G, Zhang D, et al
    Effect of preoperative PI-RADS assessment on pathological outcomes in patients who underwent radical prostatectomy.
    Cancer Imaging. 2023;23:113.
    

    >> Share

    
    
26. LUO L, Zheng A, Chang R, Li Y, et al
    Evaluating the value of (18)F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard.
    Cancer Imaging. 2023;23:108.
    

    >> Share

    
    September 2023
27. HU B, Zhang H, Zhang Y, Jin Y, et al
    A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naive patients.
    Cancer Imaging. 2023;23:82.
    

    >> Share

    
    
28. YANG J, Li J, Xiao L, Zhou M, et al
    (68)Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone.
    Cancer Imaging. 2023;23:81.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share